Superior chronic tolerability of adjunctive modafinil compared to pramipexole in treatment-resistant bipolar disorder.

@article{DellOsso2013SuperiorCT,
  title={Superior chronic tolerability of adjunctive modafinil compared to pramipexole in treatment-resistant bipolar disorder.},
  author={B. Dell’Osso and Sara Timtim and F. Hooshmand and S. Miller and Po W. Wang and S. J. Hill and N. Portillo and T. Ketter},
  journal={Journal of affective disorders},
  year={2013},
  volume={150 1},
  pages={
          130-5
        }
}
BACKGROUND Suboptimal outcomes are common in bipolar disorder (BD) pharmacotherapy, and may be mitigated with novel adjunctive agents such as modafinil (a low-affinity dopamine transport inhibitor) and pramipexole (a dopamine D2/D3 receptor agonist). While uncontrolled long-term effectiveness data have been reported for these treatments, reports specifically assessing their comparative acute versus chronic tolerability in BD are lacking. Such information, particularly in relation to… Expand
Assessing efficacy/effectiveness and safety/tolerability profiles of adjunctive pramipexole in bipolar depression: acute versus long-term data
TLDR
Adjunctive pramipexole may be a valid option in both the acute and the long-term treatment of drug-resistant bipolar depression, with possible superior tolerability in the short term. Expand
Study protocol for a randomised placebo-controlled trial of pramipexole in addition to mood stabilisers for patients with treatment resistant bipolar depression (the PAX-BD study)
TLDR
The PAX-BD study aims to extend previous findings by assessing the efficacy, safety and health economic impact of pramipexole in addition to mood stabilisers for patients with TRBD. Expand
Assessing the Roles of Stimulants/Stimulant-like Drugs and Dopamine-agonists in the Treatment of Bipolar Depression
TLDR
Findings from reviewed studies suggested that pro-dopaminergic compounds, such as pramipexole and stimulants/stimulant-like agents, deserve consideration as adjunctive therapies in bipolar depressed patients, at least in some subgroups of patients. Expand
Bipolar affective disorder: A review of novel forms of therapy
TLDR
The results of recent investigations of ketamine, modafinil and tamoxifen, including their receptor mechanisms, as well as certain genetic aspects or elements of their pharmacodynamics, for use in BD therapy are introduced. Expand
Use of Stimulants in Bipolar Disorder
TLDR
The aims are to summarize available literature on the use of stimulants in bipolar patients, discuss practical management implications, and suggest MPH might be an option in some bipolar forms observed in psychiatric presentations of frontotemporal dementia and traumatic brain injury. Expand
Repurposed drugs for the treatment of schizophrenia and bipolar disorders.
TLDR
The current evidence of selected drugs whose repurposed use might expand the range of treatment options for schizophrenia and bipolar disorders is reviewed. Expand
Pharmacological Approaches for Treatment-resistant Bipolar Disorder
TLDR
There is a striking paucity of research on experimental treatments for patients with bipolar disorder, mainly involving small incompletely controlled trials of add-on treatment, and findings remain preliminary. Expand
Pharmacokinetic and pharmacodynamic of the cognitive enhancer modafinil: Relevant clinical and forensic aspects
TLDR
Modafinil is a nonamphetamine nootropic drug with an increasingly therapeutic interest due to its different sites of action and behavioral effects in comparison to cocaine or amphetamine, and its psychotropic and cognitive effects are also attractive in several other pathologies and conditions that affect sleep structure, induce fatigue and lethargy, and impair cognitive abilities. Expand
The Effects of the Atypical Dopamine Uptake Inhibitor CE-158 on Extracellular Dopamine in the Nucleus Accumbens
Major Depressive Disorder (MDD) is characterized by symptoms such as cognitive dysfunctions, inflammatory changes, and motivational symptoms such as amotivation, fatigue, and anergia. While depressedExpand
The dopamine hypothesis of bipolar affective disorder: the state of the art and implications for treatment
TLDR
Converging findings from pharmacological and imaging studies support the hypothesis that a state of hyperdopaminergia, specifically elevations in D2/3 receptor availability and a hyperactive reward processing network, underlies mania, and a failure of dopamine receptor and transporter homoeostasis might underlie the pathophysiology of this disorder. Expand
...
1
2
...

References

SHOWING 1-10 OF 45 REFERENCES
Assessing efficacy/effectiveness and safety/tolerability profiles of adjunctive pramipexole in bipolar depression: acute versus long-term data
TLDR
Adjunctive pramipexole may be a valid option in both the acute and the long-term treatment of drug-resistant bipolar depression, with possible superior tolerability in the short term. Expand
A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression.
TLDR
These data suggest that adjunctive modafinil at doses of 100-200 mg a day may improve depressive symptoms in patients with bipolar disorder. Expand
Pramipexole in treatment‐resistant depression: An extended follow‐up
TLDR
Pramipexole augmentation of antidepressant treatment was relatively safe and presumably effective in the long‐term course of treatment resistant depression. Expand
Use of adjunctive stimulants in adult bipolar depression.
TLDR
An updated perspective on the use of stimulants and stimulant-like medications in adult bipolar depression is provided, considering not only recent randomized controlled trials, but also open naturalistic studies, in order to clarify the strengths and limitations of using these agents. Expand
Absence of mood switch with and tolerance to modafinil: a replication study from a large private practice.
TLDR
Adult affective disorder patients, whether unipolar or bipolar, can use modafinil to relieve symptoms of depression, including fatigue and sleepiness, without risking a switch in their mood or developing tolerance or abuse of this medication. Expand
Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression.
TLDR
A preliminary randomized, placebo-controlled trial to determine the safety and antidepressant efficacy of pramipexole in treatment-resistant bipolar depression found it was a safe and effective antidepressant among patients with bipolar depression. Expand
Pharmacokinetic evaluation of pramipexole
TLDR
The overall pharmacokinetic profile of pramipexole for both the IR and ER formulations is summarized and the opportunity to provide more continuous drug delivery in a fashion that could help minimize dyskinesia risk is considered. Expand
Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder.
TLDR
Adjunctive armodafinil 150 mg/day reduced depressive symptoms associated with bipolar I disorder to a greater extent than adjunctive placebo, although the difference failed to reach statistical significance. Expand
Pramipexole for bipolar II depression: a placebo-controlled proof of concept study
TLDR
The dopamine agonist pramipexole was found to have significant antidepressant effects in patients with bipolar II depression and showed a significant treatment effect for total Montgomery-Asberg Depression Rating Scale scores. Expand
Modafinil: A Review of Neurochemical Actions and Effects on Cognition
TLDR
Overall, modafinil is an excellent candidate agent for remediation of cognitive dysfunction in neuropsychiatric disorders and shows initial promise for a variety of off-label indications in psychiatry. Expand
...
1
2
3
4
5
...